Tagged with ALS

clinical trials The general manager of Roche Argentina weighs up the factors that have allowed the country to be included among the top three performing markets in the region for Roche, and explains how the country has become an increasingly important location for clinical trials for the company.      What have…

innovation Javier Anitua, Managing Director of Mylan Spain, discusses the preservation of Spain’s pharmacy model, preventive solutions for pharmacists, and the need for higher generic penetration in Spain.   What more needs to be done in Spain to communicate the value that generics bring to stakeholders who set prices? The sustainability…

R&D Aplicaps was founded in 2008 with solely Spanish investments, when Spain was already suffering from a recession due to the real estate bubble. The company’s CEO, José Luis Martín Guinea, discusses the origins of the company in Portugal and the competitive services that Aplicaps offers to the Spanish pharmaceutical market.…

clinical trials Ciro Caravaggio, General Manager at Roche Chile discusses Roche’s mission as a highly specialized biotech with a long presence in Chile. He stresses the importance of the affiliate’s role in clinical trials and the key to success in the Chilean pharmaceutical market. M. Caravaggio, you arrived at the helm of…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

market access José Aranda da Silva, General Manager of Formifarma Portugal, stresses the importance of market access, demonstrating added value for companies today, as well as the need for a revamp of Portugal’s outdated reimbursement system.   What was your inspiration for creating Formifarma? Having spent my career in various fields of…

Generics Armando Esguerra, President of Chira Pharmaceuticals, Philippines, explains the concept of chirality, why it is relevant and extremely important in the pharmaceutical industry, and what have been the major challenges and successes of the company since its founding.    CHIRA Pharmaceuticals as a company was founded on the concept of…

Array In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to medium enterprises in mind, and tailored for companies that are part of emerging industries. But are these companies overvalued, and…

Clinical trials Endang W. Hoyaranda, President Director of Prodia Group, speaks about the ongoing challenges of clinical trials in Indonesia, especially in remote medical communities, and why changing the mindset from ‘guinea pig’ testing to medical advancement opportunities is key to changing the landscape of clinical trials in the country. Although Prodia…

Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…

Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…

Newbridge Pharmaceuticals Joe Henein, President & CEO of Newbridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes Newbridge Pharmaceuticals a unique partner within the industry, and expounds on the many possible options for the future of the company. Newbridge Pharmaceuticals is a unique company within the Middle…